RTsafe
Athens
About RTsafe
Founded in 2014, RTsafe is introducing Individualized Care to Radiation Oncology. It designs and manufactures the first FDA-cleared, patient-specific, anatomically-exact models of human head and brain tissue. These are offered to Radiotherapy clinics for simulating radiation therapy for each patient ahead of actual treatment in a totally risk-free environment, thus maximizing cancer patient safety and treatment effectiveness during radiation therapy. This solution is also sold to RT equipment manufacturers for machine-testing purposes. After winning a R&D 100 Award, RTsafe’s PseudoPatientTM is recognized as one of the 100 most significant high-tech products worldwide for 2019. The company’s vision is a world where every radiotherapy intervention is tested on a PseudoPatient® before the real patient.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $3.9M
- Funding stage: Early Stage Venture
- Last round: Convertible Note (Mar 2019)
- Website: rt-safe.com
- Phone: +30 210 7563691
Industries & Categories
Health Care, Medical Device, Oncology, Personalization, Quality Assurance
Social Profiles
Canonical: https://fsome.com/organization/rtsafe-44812 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.